Serine 312 phosphorylation is dispensable for wild-type p53 functions in vivo

Cell Death and Differentiation

Volumn 18, Issue 2, 2011, Pages 214-221

  Lee, M K ^a   Tong, W M ^b   Wang, Z Q ^c,d   Sabapathy, K ^a,e,f  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c FRITZ LIPMANN INSTITUTE   (Germany)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^e DUKE NUS MEDICAL SCHOOL   (Singapore)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

ER stress; p53; phosphorylation; protein stability; S312

Indexed keywords

ALANINE; PROTEIN MDM2; PROTEIN P53; SERINE;

ADULTHOOD; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL CYCLE ARREST; CELL NUCLEUS; CENTROSOME; CONTROLLED STUDY; CYTOPLASM; CYTOSOL; DEVELOPMENT; ENDOPLASMIC RETICULUM STRESS; GENE TARGETING; GENOTYPE; IN VIVO STUDY; LETHALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; UBIQUITINATION; WILD TYPE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; ENDOPLASMIC RETICULUM; GENE KNOCK-IN TECHNIQUES; GENOTYPE; MICE; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MDM2; SERINE; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINATION;

MUS;

EID: 78651277063     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2010.90     Document Type: Article

References (40)

1. Donehower LA, Lozano G. 20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer 2009;9: 831-841.
2. Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell 2009;137: 413-431.
3. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007;28: 622-629.
4. Clarke AR, Purdie CA, Harrison DJ,Morris RG, Bird CC, Hooper ML et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993;362: 849-852.
5. Lane DP, Midgley CA, Hupp TR, Lu X, Vojtesek B, Picksley SM. On the regulation of the p53 tumour suppressor, and its role in the cellular response to DNA damage. Philos Trans R Soc Lond B Biol Sci 1995;347: 83-87.
6. Piette J, Neel H, Marechal V. Mdm2: keeping p53 under control. Oncogene 1997;15: 1001-1010.
7. Olsson A, Manzl C, Strasser A, Villunger A. How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression? Cell Death Differ 2007;14: 1561-1575.
8. Rodriguez MS, Desterro JM, Lain S, Lane DP, Hay RT. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol 2000;20: 8458-8467.
9. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997;91: 325-334.
10. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004;4: 793-805.
11. Kapoor M, Lozano G. Functional activation of p53 via phosphorylation following DNA damage by UV but not gamma radiation. Proc Natl Acad Sci USA 1998;95: 2834-2837.
12. Qu L, Huang S, Baltzis D, Rivas-Estilla AM, Pluquet O, Hatzoglou M et al. Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3beta. Genes Dev 2004;18: 261-277.
13. Blaydes JP, Luciani MG, Pospisilova S, Ball HM, Vojtesek B, Hupp TR. Stoichiometric phosphorylation of human p53 at Ser315 stimulates p53-dependent transcription. J Biol Chem 2001;276: 4699-4708.
14. Fogal V, Hsieh JK, Royer C, Zhong S, Lu X. Cell cycle-dependent nuclear retention of p53 by E2F1 requires phosphorylation of p53 at Ser315. Embo J 2005;24: 2768-2782.
15. Wang Y, Eckhart W. Phosphorylation sites in the amino-terminal region of mouse p53. Proc Natl Acad Sci USA 1992;89: 4231-4235.
16. Wang Y, Prives C. Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases. Nature 1995;376: 88-91.
17. Xu Y. Regulation of p53 responses by post-translational modifications. Cell Death Differ 2003;10: 400-403.
18. Samad A, Anderson CW, Carroll RB. Mapping of phosphomonoester and apparent phosphodiester bonds of the oncogene product p53 from simian virus 40-transformed 3T3 cells. Proc Natl Acad Sci USA 1986;83: 897-901.
19. Meek DW, Eckhart W. Phosphorylation of p53 in normal and simian virus 40-transformed NIH 3T3 cells. Mol Cell Biol 1988;8: 461-465.
20. Reynolds R, Witherspoon S, Fox T. The infant mouse as a in vivo model for the detection and study of DNA damage-induced changes in the liver. Mol Carcinog 2004;40: 62-72.
21. Midgley CA, Owens B, Briscoe CV, Thomas DB, Lane DP, Hall PA. Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo. J Cell Sci 1995;108 (Pt 5): 1843-1848.
22. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387: 296-299.
23. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997;420: 25-27.
24. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387: 299-303.
25. Lee MK, Sabapathy K. Phosphorylation at carboxyl-terminal S373 and S375 residues and 14-3-3 binding are not required for mouse p53 function. Neoplasia 2007;9: 690-698.
26. Tarapore P, Fukasawa K. Loss of p53 and centrosome hyperamplification. Oncogene 2002;21: 6234-6240.
27. Hao M, Lowy AM, Kapoor M, Deffie A, Liu G, Lozano G. Mutation of phosphoserine 389 affects p53 function in vivo. J Biol Chem 1996;271: 29380-29385.
28. Hengstermann A, Whitaker NJ, Zimmer D, Zentgraf H, Scheffner M. Characterization of sequence elements involved in p53 stability regulation reveals cell type dependence for p53 degradation. Oncogene 1998;17: 2933-2941.
29. Liang SH, Hong D, Clarke MF. Cooperation of a single lysine mutation and a C-terminal domain in the cytoplasmic sequestration of the p53 protein. J Biol Chem 1998;273: 19817-19821.
30. Lu W, Chen L, Peng Y, Chen J. Activation of p53 by roscovitine-mediated suppression of MDM2 expression. Oncogene 2001;20: 3206-3216.
31. Sakaguchi K, Sakamoto H, Lewis MS, Anderson CW, Erickson JW, Appella E et al. Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. Biochemistry 1997;36: 10117-10124.
32. Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F et al. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 2004;36: 55-62.
33. Iwakuma T, Lozano G. Crippling p53 activities via knock-in mutations in mouse models. Oncogene 2007;26: 2177-2184.
34. MacPherson D, Kim J, Kim T, Rhee BK, Van Oostrom CT, DiTullio RA et al. Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO J 2004;23: 3689-3699.
35. Bruins W, Zwart E, Attardi LD, Iwakuma T, Hoogervorst EM, Beems RB et al. Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. Mol Cell Biol 2004;24: 8884-8894.
36. Sluss HK, Armata H, Gallant J, Jones SN. Phosphorylation of serine 18 regulates distinct p53 functions in mice. Mol Cell Biol 2004;24: 976-984.
37. Lin T, Chao C, Saito S, Mazur SJ, Murphy ME, Appella E et al. p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol 2005;7: 165-171.
38. Brodsky MH, Weinert BT, Tsang G, Rong YS, McGinnis NM, Golic KG et al. Drosophila melanogaster MNK/Chk2 and p53 regulate multiple DNA repair and apoptotic pathways following DNA damage. Mol Cell Biol 2004;24: 1219-1231.
39. Phang BH, Sabapathy K. The codon 72 polymorphism-specific effects of human p53 are absent in mouse cells: implications on generation of mouse models. Oncogene 2007;26: 2964-2974.
40. Lee MK, Sabapathy K. The R246S hot-spot p53 mutant exerts dominant-negative effects in embryonic stem cells in vitro and in vivo. J Cell Sci 2008;121 (Pt 11): 1899-1906.